ArticleResearch square2024
Precision targeting of β-catenin induces tumor reprogramming and immunity in hepatocellular cancers.
Abstract readPreprint
In one paragraph
Article in Research square, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Updated by
Authors and funding
34 authors.
Brandon M LehrichDepartment of Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Evan R DelgadoPittsburgh Liver Research Center, University of Pittsburgh and University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
Tyler M YasakaDepartment of Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Silvia LiuDepartment of Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Catherine CaoDepartment of Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Yuqing LiuDepartment of Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Mohammad TaheriDepartment of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Xiangnan GuanTranslational Medicine, Genentech Inc., San Francisco, CA, USA.
Hartmut KoeppenTranslational Medicine, Genentech Inc., San Francisco, CA, USA.
Sucha SinghDepartment of Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Jia-Jun LiuDepartment of Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Anya Singh-VarmaDepartment of Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Yekaterina KrutsenkoDepartment of Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Minakshi PoddarDepartment of Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
T Kevin HitchensUniversity of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
Lesley M FoleyUniversity of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
Binyong LiangHepatic Surgery Center, Department of Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Alex RialdiDepartment of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY.
Ravi P RaiDepartment of Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Panari PatelDepartment of Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Madeline RileyDepartment of Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Aaron BellDepartment of Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.ORCID https://orcid.org/0000-0001-6648-0834
Reben RaemanDepartment of Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Tulin DadaliAlnylam Pharmaceuticals, Boston, MA, USA.
Jason J LukeUPMC Hillman Cancer Center and University of Pittsburgh, Pittsburgh, PA.ORCID https://orcid.org/0000-0002-1182-4908
Ernesto GuccioneDepartment of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY.ORCID https://orcid.org/0000-0001-7764-5307
Mo R EbrahimkhaniDepartment of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.ORCID https://orcid.org/0000-0001-5753-6779
Amaia LujambioDepartment of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY.ORCID https://orcid.org/0000-0002-2798-1481
Xin ChenCancer Biology Program, University of Hawaii Cancer Center, Honolulu, HI, USA.ORCID https://orcid.org/0000-0002-9588-0164
Martin MaierAlnylam Pharmaceuticals, Boston, MA, USA.
Yulei WangTranslational Medicine, Genentech Inc., San Francisco, CA, USA.ORCID https://orcid.org/0000-0002-9057-9786
Wendy BroomAlnylam Pharmaceuticals, Boston, MA, USA.
Junyan TaoDepartment of Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Satdarshan P MongaDepartment of Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.ORCID https://orcid.org/0000-0002-8437-3378
Funding
VECTOR CORE FACILITYP30CA047904 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI CHRISTOPHER J. BAKKENIST · 1988 to 2026
$158.0MPittsburgh Liver Research CenterP30DK120531 · NIDDK · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Shuchang Silvia Liu · 2019 to 2026
$10.9MNCI ET-CTN with Phase i Emphasis at UPCIUM1CA186690 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI JOHN C. BYRD, Farshid Dayyani · 2014 to 2026
$9.1MCellular Approaches to Tissue Engineering/RegenerationT32EB001026 · NIBIB · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI DUNCAN, ANDREW W, MONGA, SATDARSHAN SINGH · 2003 to 2024
$5.5MTargeting tumor metabolism and immune environment via beta-catenin: Towards precision medicine in HCCR01CA251155 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI LUJAMBIO, AMAIA, MONGA, SATDARSHAN SINGH · 2020 to 2024
$3.1MInvestigating Multifactorial Beta-catenin Activation in Hepatocellular CancersR01CA250227 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Xin Chen, Satdarshan Singh Monga · 2021 to 2026
$3.0MAn immunocompetent platform for the characterization and discovery of novel therapeutics for hepatocellular carcinomaK99CA273538 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI RIALDI, ALEXANDER · 2022 to 2023
$343kInvestigating Immunosuppression in Beta-catenin-mutated Hepatocellular Carcinoma for Improved Precision Medicine TherapeuticsF30CA284540 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI LEHRICH, BRANDON · 2023 to 2025
$161kNCI NIH HHS F30 CA284540NCI NIH HHS K99 CA273538NCI NIH HHS P30 CA047904NCI NIH HHS R01 CA250227NCI NIH HHS R01 CA251155NCI NIH HHS UM1 CA186690NIBIB NIH HHS T32 EB001026NIDDK NIH HHS P30 DK120531
Abstract
First-line immune checkpoint inhibitor (ICI) combinations show responses in subsets of hepatocellular carcinoma (HCC) patients. Nearly half of HCCs are Wnt-active with mutations in
Indexed as
hepatocellular carcinomaimmunotherapymolecular therapyprecision medicinesingle cellspatial transcriptomicsWntβ-catenin
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.